In a report released today, Stephen Brozak from WBB Securities reiterated a Buy rating on Athersys, with a price target of $9. The company’s shares closed yesterday at $2.13.
“We believe the confidence that Healios has demonstrated in ATHX, through licensing and financial investment, plus the long-term results in prior MultiStem therapy stroke trials bring us to the conclusion that MultiStem therapy could represent a significant breakthrough in off-the-shelf, non-fetal-derived, allogeneic, stem cell therapy. We are therefore re-iterating our 12-month price target of $9 a share. Healios will demonstrate its commitment to and confidence in the use of MultiStem therapy for stroke treatment by exercising a $15 million option on December 6. This is in addition to the $41.1 million already invested. The option will award Healios an exclusive license to use MultiStem products for the treatment of one or more of ischemic stroke, ARDS, and either trauma or an alternative mutually agreed-upon indication in China.”
Brozak has an average return of 6.5% when recommending Athersys.
According to TipRanks.com, Brozak is ranked #842 out of 4884 analysts.
Athersys has an analyst consensus of Moderate Buy, with a price target consensus of $7.50.
In a report released today, Craig Bijou from Cantor Fitzgerald reiterated a Buy rating on AxoGen, with a price target of $45. The company’s shares closed yesterday at $37.23.
“We reiterate our Overweight rating and a 12-month target price of $45 on shares of AXGN. We think AXGN is one of the most compelling growth stories in medtech, with a 50+% CAGR over the last three years and what we believe is sustainable top- line growth of around 40% for the next two years. AXGN has the only commercially available nerve allograft to repair peripheral nerves. We expect utilization to accelerate as favorable clinical and economic data builds and increases surgeon awareness. We would also expect the company to continue to pursue additional market opportunities, as the technology is applicable to nerves across the body.”
According to TipRanks.com, Bijou is a 5-star analyst with an average return of 22.7% and a 78.4% success rate. Bijou covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and Wright Medical Group.
AxoGen has an analyst consensus of Moderate Buy, with a price target consensus of $44.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.